Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Tatneft increased oil production by almost 5% in 2022

3/20/23 TATN

Lukoil seeks to expand its presence in Congo

3/20/23 LKOH

Lukoil may make an investment decision on Ghana offshore field in October-November

3/20/23 LKOH

Board of Directors of Primorie Bank recommended that dividends be paid for 2022

3/20/23 PRMB

UBS to acquire Credit Suisse for $3.2 billion

3/20/23 UBSG

UnitedHealth reports for 2022

3/17/23 UNH

Profit of LSR by the end of 2022 decreased by 17.9%

3/17/23 LSRG

LSR reported for 2022 according to RAS

3/17/23 LSRG

Polymetal sold the East-Tarutinsky project in Kazakhstan

3/17/23 POLY

Tatneft reported for 2022 according to RAS

3/17/23 TATN